Gut-selective treatment now funded publicly for Canadians with ulcerative colitis and Crohn's disease
OAKVILLE, ON, May 9, 2017 /CNW/ - Takeda Canada Inc. is pleased to announce that several provinces across Canada including Ontario and British Columbia, have agreed to fund ENTYVIO® (vedolizumab), the first and only gut-selective biologic therapy for inflammatory bowel disease (IBD) through their public provincial drug plans.
ENTYVIO® is now funded in Ontario and British Columbia for adults with moderate or severe biologic-naïve and biologic-experienced ulcerative colitis (UC) or Crohn's disease (CD).
"We are seeing in clinical practice what we expected of ENTYVIO® from its clinical studies – that it is an effective option for patients with IBD moving to biologic therapy," said Dr. Brian Feagan, a gastroenterologist and Director of Robarts Clinical Trials at the Robarts Research Institute in London, Ontario. "Being able to offer ENTYVIO® to manage the debilitating symptoms of IBD is excellent news for physicians and patients."
The listings follow the successful conclusion of negotiations between Takeda Canada Inc. and the pan-Canadian Pharmaceutical Alliance (pCPA), the body set up by all the provinces and territories to jointly negotiate terms of public drug plan listings with pharmaceutical companies.1 ENTYVIO® is already covered by almost all private insurers in Canada, but many Canadians with IBD rely on public provincial plans for their treatments.
"The unique gut-selective mode of action with this treatment is an important attribute because it directly targets the disease, which leaves less potential for side effects," said Dr. Brian Bressler, Director of the Advanced IBD Training Program and Clinical Associate Professor of Medicine at the University of British Columbia in Vancouver. "We have seen good results with many patients to date and are pleased that it will be available to more patients now that it is available through provincial public drug plans."
In addition to British Columbia and Ontario, ENTYVIO® is now available through public drug plans in Yukon and Nova Scotia for adults with moderate to severe UC or CD who have failed conventional therapy or biological therapy such as anti-TNF therapy.
In Saskatchewan ENTYVIO® has been added to its public formulary as an exception drug benefit for the treatment of UC in patients unresponsive to high-dose intravenous steroids.
In Quebec, ENTYVIO® is available for bio-naïve and bio-experienced adults with UC and for CD it is available after failure on all funded anti-TNF therapies or in those contraindicated to receive or unable to tolerate anti-TNFs therapies.
"Canadians living with Crohn's and/or colitis need access to drugs and treatments that could alleviate their symptoms and help them achieve remission which has a huge impact on quality of life," said Mina Mawani, President and CEO, Crohn's and Colitis Canada. "This news is very encouraging and we are pleased that patients will have access to ENTYVIO® through their public drug plans. We now need to see this translated into availability in all provinces as soon as possible so all Canadians living with these chronic diseases have the same opportunity to improve their quality of life."
ENTYVIO® is Takeda Canada's innovative biologic treatment for the two most common types of IBD, CD and UC.2 ENTYVIO® was the 2016 winner of the prestigious Prix Galien Canada - Innovative Product Award, recognizing its unique mode of action and ability to offer an efficacious gut-selective treatment option for patients living with moderate to severe UC or CD.3
"We are very pleased that Ontario, British Columbia and other public drug plans have recognized the need for additional IBD treatment options and will continue our discussions so Canadians with UC and CD in all provinces can benefit," said Chatrick Paul, General Manager of Takeda Canada. "ENTYVIO® has been enthusiastically received by physicians and patients since it was first approved in Canada in 2015 and we know it is anxiously awaited by those who depend on public drug plans."
Patients who are prescribed ENTYVIO® are fully supported with information, reimbursement assistance and convenient infusion clinics through Takeda's patient support program YOURVANTAGE™.
About inflammatory bowel disease (IBD)
The two most common forms of IBD are ulcerative colitis (UC) and Crohn's disease (CD).4 Approximately 233,000 Canadians are living with UC and CD. More than 10,000 new cases are diagnosed each year, typically in patients in their 20s, though it can be diagnosed at any age, including in children.5 IBD has been labelled Canada's "national disease" due to Canada having among the highest rates in the world.6 UC causes the tissue of the large intestine (including the colon and rectum) to become inflamed, form sores and bleed easily. Along with symptoms of abdominal pain, cramping, diarrhea, nausea and vomiting, UC can cause severe complications including intestinal bleeding and bowel obstructions. CD may involve inflammation in different parts of the gastrointestinal (GI) tract in different people; however, it most commonly affects the lower part of the small intestine (the ileum) where it joins the beginning of the colon.7 Sometimes a portion of the bowel needs to be surgically removed to bring patients relief.8 The exact cause of IBD is not entirely understood, though it is believed to result from an interaction between genes and the body's immune system, with environmental factors possibly playing a role.9
ENTYVIO® is the first and only gut-selective biologic therapy with no known systemic immunosuppressive effects10 and works by targeting the gut, directly reaching inflammation that causes symptoms of ulcerative colitis and Crohn's disease.11 ENTYVIO® is approved by Health Canada for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a TNFα antagonist.12 ENTYVIO® is also indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a tumor necrosis factor-alpha (TNFα) antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.13
Canadian researchers played a pivotal role in the treatment's early discovery and development. Researcher Dr. Andrew Lazarovits of London, Ontario, developed a first potential molecule for this type of therapy while working in Boston but passed away in 1999 at age 44.14 His work was taken up by others, resulting in the development of vedolizumab and eventually international clinical trials financed by Takeda which were led by Dr. Feagan in London, Ontario. The treatment was first used on an ulcerative colitis patient at University Hospital in London15 and Dr. Feagan was the lead author of the publication of the trial results in The New England Journal of Medicine in 2013.16
Takeda's Commitment to Gastroenterology
More than 70 million people worldwide are impacted by gastrointestinal (GI) diseases, which can be complex, debilitating and life-changing.17 Takeda is driven to improving the lives of patients with GI diseases through innovative medicines, dedicated patient disease management support and the evolution of the healthcare environment. Takeda is leading in gastroenterology through the delivery of innovative medicines in areas associated with high unmet needs, such as inflammatory bowel disease, GI acid-related diseases and GI motility disorders. Our GI research & development team is also exploring solutions in celiac disease and nonalcoholic steatohepatitis (NASH), as well as scientific advancements through microbiome therapies. With more than 25 years of experience in this area, our broad approach to treating many diseases that impact the GI system and our global network of collaborators, Takeda aims to advance how patients manage their disease.
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available at takeda.com.
Takeda Canada, located in Oakville, Ontario, is the Canadian sales and marketing organization of Takeda Pharmaceutical Company Limited. Takeda Canada is transforming to become an agile specialty pharmaceutical company, focusing on gastroenterology and oncology, while continuing to meet a number of important primary care needs. Additional information about Takeda Canada is available at takedacanada.com.
ENTYVIO® is a registered trademark of Millennium Pharmaceuticals, Inc. and used under licence by Takeda Canada Inc.
YOURVANTAGE™ is a trademark of Takeda Canada Inc.
1 Benefits Canada, How the pan-Canadian Pharmaceutical Alliance works; accessed March 13, 2017, at: http://www.benefitscanada.com/benefits/health-benefits/how-the-pan-canadian-pharmaceutical-alliance-works-81307
2 Crohn's and Colitis Canada, Newly Diagnosed; accessed April 25, 2017, at: http://www.crohnsandcolitis.ca/Living-with-Crohn-s-Colitis/Diagnostic-recent
3 Prix Galien Canada, 2016 Laureates; accessed March 13, 2017 at: http://eng.prix-galien-canada.com/2016-laureates.html
4 Crohn's and Colitis Canada, Newly Diagnosed; accessed April 25, 2017, at: http://www.crohnsandcolitis.ca/Living-with-Crohn-s-Colitis/Diagnostic-recent
5 Crohn's and Colitis Canada, The Impact of IBD Report, Who is affected; accessed April 25, 2017, at: http://crohnsandcolitis.ca/About-Us/Resources-Publications/Impact-of-IBD-Report
6 Media Planet, Digestive Wellness Supplement, Tackling the burden of ulcerative colitis, March 2015, accessed March 13, 2017, at: http://www.personalhealthnews.ca/prevention-and-treatment/tackling-the-burden-of-ulcerative-colitis
7 Crohn's and Colitis Canada, The impact of inflammatory bowel disease in Canada, 2012 final report, page 17, accessed April 25, 2017, at: http://crohnsandcolitis.ca/About-Us/Resources-Publications/Impact-of-IBD-Report
8 Crohn's and Colitis Canada, The impact of inflammatory bowel disease in Canada, 2012 final report, page 20 and 22, accessed April 25, 2017, at: http://crohnsandcolitis.ca/About-Us/Resources-Publications/Impact-of-IBD-Report
9 Crohn's and Colitis Foundation of America, The Facts about Inflammatory Bowel Disease, page 5, accessed March 13, 2017, at: http://www.ccfa.org/assets/pdfs/updatedibdfactbook.pdf
10 Feagan BG et al, Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, N Engl J Med 2013; 369:699-710, August 22, 2013, page 700, accessed March 13, 2017, at: http://www.nejm.org/doi/full/10.1056/NEJMoa1215734
11 Takeda Canada Inc., ENTYVIO® (vedolizumab) Product Monograph, November 11, 2016, p. 3.
12 Takeda Canada Inc., ENTYVIO® (vedolizumab) Product Monograph, November 11, 2016, p. 3., and Health Canada Notice of Compliance information. Available at: https://health-products.canada.ca/noc-ac/info.do?lang=en&no=16576 Accessed May 4, 2017.
13 Takeda Canada Inc., ENTYVIO® (vedolizumab) Product Monograph, November 11, 2016, p. 3., and Health Canada Notice of Compliance information. Available at: https://health-products.canada.ca/noc-ac/info.do?lang=en&no=17908 Accessed May 4, 2017.
14 Feagan BG et al, Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin, Clinical Gastroenterology and Hepatology, 2008; 6:12, 1370–1377 accessed March 13, 2017, at: http://www.cghjournal.org/article/S1542-3565%2808%2900617-4/abstract and Sher J, Approval being sought for new treatment for Crohn's and colitis, The London Free Press, Aug. 21, 2013, accessed March 13, 2017, at: http://www.lfpress.com/2013/08/21/approval-being-sought-for-new-treatment-for-crohns-and-colitis
15 Sher J, Approval being sought for new treatment for Crohn's and colitis, The London Free Press, Aug. 21, 2013, accessed March 13, 2017, at: http://www.lfpress.com/2013/08/21/approval-being-sought-for-new-treatment-for-crohns-and-colitis
16 Feagan BG et al, Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, N Engl J Med 2013; 369:699-710, August 22, 2013, accessed March 13, 2017, at: http://www.nejm.org/doi/full/10.1056/NEJMoa1215734
17 Digestive Health. University of Miami Hospital. http://umiamihospital.com/service-lines/digestive-health. Accessed April 24, 2017.
SOURCE Takeda Canada Inc.
For further information: Media contact: Natacha Raphael, Corporate Communications, Takeda Canada Inc., Tel: 905-465-4149, firstname.lastname@example.org